Leukemia Research Reports最新文献_第2页

Synergistic effects of arsenic trioxide and atorvastatin on proliferation and apoptosis in acute lymphoblastic leukemia cells 三氧化二砷和阿托伐他汀对急性淋巴细胞白血病细胞增殖和凋亡的协同作用

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-02-16 DOI: 10.1016/j.lrr.2026.100570

Sepideh Hassanpour Khodaei , Shahnaz Sabetkam , Zeinab Mazloumi , Ali Rafat , Diana Hekari , Khadijeh Dizaji Asl

{"title":"Synergistic effects of arsenic trioxide and atorvastatin on proliferation and apoptosis in acute lymphoblastic leukemia cells","authors":"Sepideh Hassanpour Khodaei , Shahnaz Sabetkam , Zeinab Mazloumi , Ali Rafat , Diana Hekari , Khadijeh Dizaji Asl","doi":"10.1016/j.lrr.2026.100570","DOIUrl":"10.1016/j.lrr.2026.100570","url":null,"abstract":"<div><div>Statins and arsenic trioxide (ATO) are known for their significant anti-neoplastic properties; however, limited research has investigated their potential synergistic effects. This study explores the individual and combined impact of ATO and atorvastatin on programmed cell death and proliferation in acute lymphoblastic leukemia (ALL) cell model. The ALL cell line was exposed to different doses of atorvastatin and ATO, both individually and in combination, to evaluate their respective IC50 values and identify the most effective concentrations. The proportions of apoptotic cells were quantified using Annexin V/PI staining, while Ki-67 expression, a well-established marker of cell proliferation, was assessed through flow cytometry. The findings revealed that atorvastatin and ATO, at concentrations of 12.4 µM and 3.34 µM, respectively, significantly enhanced apoptosis in ALL cells. Moreover, the combination therapy resulted in a marked increase in anti-proliferative effects. These findings provide new insights into the potential use of ATO and atorvastatin as a combined therapeutic strategy, highlighting their promise as a novel approach in the treatment of ALL.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100570"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147656359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Encouraging response rates and high mobilization success with brentuximab vedotin plus GDP in adult relapsed/refractory classical Hodgkin lymphoma: A real-world study brentuximab vedotin + GDP治疗成人复发/难治性经典霍奇金淋巴瘤的令人鼓舞的缓解率和高动员成功率：一项现实世界的研究

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-04-12 DOI: 10.1016/j.lrr.2026.100584

Sinem Namdaroğlu, Hikmetullah Batgi, Merve Kakcı, Osman Can Öztürk, Ömer Şeker, Berna Güzel, Kardelen Tayfur, Semih Başcı

{"title":"Encouraging response rates and high mobilization success with brentuximab vedotin plus GDP in adult relapsed/refractory classical Hodgkin lymphoma: A real-world study","authors":"Sinem Namdaroğlu, Hikmetullah Batgi, Merve Kakcı, Osman Can Öztürk, Ömer Şeker, Berna Güzel, Kardelen Tayfur, Semih Başcı","doi":"10.1016/j.lrr.2026.100584","DOIUrl":"10.1016/j.lrr.2026.100584","url":null,"abstract":"<div><h3>Background</h3><div>Relapsed or refractory classical Hodgkin lymphoma (R/R cHL) remains challenging, and achieving metabolic complete response prior to autologous stem cell transplantation (ASCT) is important. GDP is a generally well-tolerated outpatient regimen, while brentuximab vedotin (BV) has demonstrated encouraging activity in salvage combinations. Adult real-world data on BV+GDP remain limited.</div></div><div><h3>Methods</h3><div>Eight adult R/R cHL patients received BV+GDP between May 2023 and March 2025. Responses (Lugano 2014), toxicities (CTCAE v5.0), and mobilization outcomes were retrospectively evaluated.</div></div><div><h3>Results</h3><div>Complete response was achieved in 7/8 patients (87.5%). All responders underwent successful stem-cell mobilization and ASCT. Toxicities were manageable, with no febrile neutropenia or renal toxicity observed. At a median follow-up of 10.6 months, all patients remained alive and progression-free.</div></div><div><h3>Conclusion</h3><div>BV+GDP showed encouraging activity with acceptable tolerability, supporting further prospective evaluation.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100584"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147746586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report 暂时使用依鲁替尼后CLL/SLL的richter样转化：1例报告

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-03-02 DOI: 10.1016/j.lrr.2026.100578

Tung-Lin Chiang , John Frater , Amanda Cashen

引用次数: 0

Therapeutic outcomes of acute promyelocytic leukemia in children 儿童急性早幼粒细胞白血病的治疗效果

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-02-15 DOI: 10.1016/j.lrr.2026.100569

Sirine Chatti, Emna Azza, Marwa Bahri, Roua Hsasna, Yosr Ben Abdennebi, Lamia Aissaoui

引用次数: 0

Leukocytosis and a JAK2 mutation: The importance of expertise in somatic variant interpretation 白细胞增多症和JAK2突变：体细胞变异解释专业知识的重要性

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-01-13 DOI: 10.1016/j.lrr.2026.100563

Christian J. Puzo , Karl Hager , Michal Rose , Ellice Wong , Christopher A. Tormey , Alexa J. Siddon

引用次数: 0

The synergistic tumor suppressor effect of CDK4/6 inhibitors and BRD4 inhibitors in acute myeloid leukemia CDK4/6抑制剂和BRD4抑制剂在急性髓性白血病中的协同抑瘤作用

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2025-12-20 DOI: 10.1016/j.lrr.2025.100558

Kaiqiong Liao , Chong Guo , Min Zhang , Xiaobin Lv , Jinhua Yan

{"title":"The synergistic tumor suppressor effect of CDK4/6 inhibitors and BRD4 inhibitors in acute myeloid leukemia","authors":"Kaiqiong Liao , Chong Guo , Min Zhang , Xiaobin Lv , Jinhua Yan","doi":"10.1016/j.lrr.2025.100558","DOIUrl":"10.1016/j.lrr.2025.100558","url":null,"abstract":"<div><h3>Objective</h3><div>The objective of this research is to explore the anti-leukemic properties of CDK4/6 inhibitors when used alongside BET inhibitors for treating acute myeloid leukemia (AML), as well as to clarify the molecular mechanisms involved.</div></div><div><h3>Methods</h3><div>Cell viability was assessed using the CCK-8 assay following treatment of AML cells with varying doses of SHR6390, a CDK4/6 inhibitor, and OTX015, a BET inhibitor.The time- and dose-dependent inhibitory effects of these two drugs on AML cells were assessed, and the respective IC50 and combination index (CI) values after co-treatment were calculated. The effects of SHR6390 and OTX015 on the growth potential of AML cells were additionally examined through soft agar colony formation assays and flow cytometry. Furthermore, RNA sequencing and Western blot analysis were conducted on cells treated with both drugs. The aim of this study is to explore the mechanism by which SHR6390 and OTX015 synergistically inhibit the proliferation of AML cells.The anti-tumor activity of SHR6390 and/or OTX015 in AML xenograft mice was also investigated through animal experiments.</div></div><div><h3>Results</h3><div>1. Either the CDK4/6 inhibitor SHR6390 or the BRD4 inhibitor OTX015, or a combination of the two, were employed to hinder both the survival and proliferation of cell lines associated with acute myeloid leukemia, showing a synergistic effect. 2. The combined application of SHR6390 and OTX015 markedly suppresses the invasive and migratory capacities of acute myeloid leukemia cells.3. The use of both SHR6390 and OTX015 induces apoptosis in acute myeloid leukemia cells while also disrupting cell cycle progression, leading to a halt before DNA replication occurs. 4. SHR6390 and OTX015 hinder the proliferation of acute myeloid leukemia cells by targeting both the PI3K-AKT-mTOR and the Wnt-β-Catenin pathway. 5. SHR6390 and OTX015 Synergistically Inhibit the Growth of AML Xenografts In Vivo.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100558"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synergistic effects of luspatercept and cyclosporine A in lower-risk myelodysplastic syndrome with red cell aplasia: Two case insights luspatercept和环孢素A在低风险骨髓增生异常综合征伴红细胞发育不全中的协同作用：两例观察

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-03-24 DOI: 10.1016/j.lrr.2026.100582

Tatsuro Jo , Takahiro Sakai , Kazuhiro Noguchi , Kaori Yamaguchi , Kaho Umemoto , Kuniko Abe , Kazuto Shigematsu

{"title":"Synergistic effects of luspatercept and cyclosporine A in lower-risk myelodysplastic syndrome with red cell aplasia: Two case insights","authors":"Tatsuro Jo , Takahiro Sakai , Kazuhiro Noguchi , Kaori Yamaguchi , Kaho Umemoto , Kuniko Abe , Kazuto Shigematsu","doi":"10.1016/j.lrr.2026.100582","DOIUrl":"10.1016/j.lrr.2026.100582","url":null,"abstract":"<div><div>Luspatercept, an erythroid maturation agent, treats anemia in lower-risk myelodysplastic syndromes (MDS) by inhibiting SMAD2/3 signaling. However, its efficacy may be limited in immune-mediated erythroid suppression. We present two lower-risk MDS cases (per the Revised International Prognostic Scoring System) that developed red cell aplasia and poor response to luspatercept alone. Bone marrow showed near absence of erythroid precursors with multilineage dysplasia. Neither patient achieved hematologic improvement with luspatercept monotherapy. Cyclosporine A (Cy-A) was added, leading to hemoglobin improvement, transfusion independence, and marrow erythropoiesis recovery. These cases indicate red cell aplasia may reflect immune-mediated suppression, limiting luspatercept efficacy. The response to Cy-A highlights the potential role of immunosuppressive therapy. Combining luspatercept with Cy-A may offer a strategy for selected patients with lower-risk MDS and erythroid aplasia. Bone marrow reassessment should be considered in patients who fail to respond to luspatercept or who develop recurrent anemia after an initial response.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100582"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147612127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Autoimmune myelofibrosis with a TLR8 gain-of-function defect 自身免疫性骨髓纤维化伴TLR8功能获得缺陷

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-04-12 DOI: 10.1016/j.lrr.2026.100587

Shiqiang Qu , Peihong Zhang , Zefeng Xu , Tiejun Qin , Bing Li , Zhijian Xiao

引用次数: 0

Targeting nucleotide metabolism and epigenetic regulation to overcome the differentiation blockade in AML 靶向核苷酸代谢和表观遗传调控克服AML的分化阻断

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-04-11 DOI: 10.1016/j.lrr.2026.100586

Shinichiro Takahashi

{"title":"Targeting nucleotide metabolism and epigenetic regulation to overcome the differentiation blockade in AML","authors":"Shinichiro Takahashi","doi":"10.1016/j.lrr.2026.100586","DOIUrl":"10.1016/j.lrr.2026.100586","url":null,"abstract":"<div><div>Differentiation blockade is a central pathogenic hallmark of acute myeloid leukemia (AML). While all-trans retinoic acid (ATRA) achieves curative differentiation in acute promyelocytic leukemia (APL), this success has not extended to other AML subtypes. Recently, inhibitors targeting nucleotide metabolism—such as cytarabine, dihydroorotate dehydrogenase (DHODH) inhibitors, and DNA hypomethylating agents—have emerged as promising candidates to overcome this therapeutic barrier. These compounds promote myeloid maturation through mechanisms involving cell-cycle arrest, epigenetic reprogramming, and replication stress–activated signaling. Preclinical and early clinical evidence suggests that targeting nucleotide metabolism may induce partial differentiation of leukemic blasts, providing a metabolic and epigenetic avenue for therapy beyond APL. This mini-review summarizes current understanding of how metabolic inhibition restores differentiation in AML, focusing on representative agents and their mechanistic and translational implications. Targeting de novo nucleotide biosynthesis may offer a metabolic and epigenetic route to expand differentiation-based strategies beyond APL.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100586"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147709403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the effectiveness of reduced-intensity conditioning regimens in acute myeloid leukemia patients after hematopoietic stem cell transplantation in Vietnam 评估越南急性髓系白血病患者造血干细胞移植后降低强度调理方案的有效性

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-04-22 DOI: 10.1016/j.lrr.2026.100590

Man Van Huynh , Huu Than Huynh , Thu Hanh Nguyen , Tong Thanh Tran , Xuan Tuan Ma , Nam Duy Hoang , Chi Dung Phu

{"title":"Evaluating the effectiveness of reduced-intensity conditioning regimens in acute myeloid leukemia patients after hematopoietic stem cell transplantation in Vietnam","authors":"Man Van Huynh , Huu Than Huynh , Thu Hanh Nguyen , Tong Thanh Tran , Xuan Tuan Ma , Nam Duy Hoang , Chi Dung Phu","doi":"10.1016/j.lrr.2026.100590","DOIUrl":"10.1016/j.lrr.2026.100590","url":null,"abstract":"<div><h3>Objective</h3><div>Hematopoietic stem cell transplantation (HSCT) is an effective treatment for acute myeloid leukemia (AML) patients, leveraging cytotoxic conditioning regimens and graft-versus-leukemia effects. Reduced-intensity conditioning (RIC) regimens extend this therapy to elderly patients and those with severe comorbidities, minimizing toxicity while maintaining efficacy. The study aims to determine the result of reduced-intensity conditioning regimens for acute myeloid leukemia patients at Blood Transfusion Hematology Hospital, Vietnam.</div></div><div><h3>Methods</h3><div>The retrospective observational study included 21 AML patients who underwent RIC from January 2021 to March 2024.</div></div><div><h3>Results</h3><div>Median recovery times for neutropenia and thrombocytopenia were 16 and 26 days, respectively. Complications included mucositis (95.2%), febrile episodes (85.7%), CMV reactivation (83.3%), acute GVHD (23.8%), and chronic GVHD (14.3%). The 2-year disease-free survival (DFS) and overall survival (OS) rates were 61.4% and 69.3%, respectively.</div></div><div><h3>Conclusions</h3><div>Reduced-intensity conditioning regimens are a safe and effective treatment option for elderly AML patients with comorbidities.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100590"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147802512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0